SMT19969 - a phase I, randomised, partially-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of single and multiple oral escalating doses in male healthy subjects

Trial Profile

SMT19969 - a phase I, randomised, partially-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of single and multiple oral escalating doses in male healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2015

At a glance

  • Drugs Ridinilazole (Primary)
  • Indications Clostridium infections
  • Focus Adverse reactions; First in man
  • Sponsors Summit plc
  • Most Recent Events

    • 13 Sep 2013 Results assessing effects of multiple doses of SMT 19969 (groups G and H) on gut flora presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 11 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 10 Sep 2013 Results were presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 2013, according to a Summit Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top